Target intelligence / Profile preview

T cell receptor alpha variable 13-2 (TRAV13-2)

Target
TRAV13-2
Molecular classification
Receptor (specifically, variable region of the T cell receptor alpha chain), Immunoglobulin superfamily (variable Ig domain)
01

Overview

T cell receptor alpha variable 13-2 (TRAV13-2) encodes the variable (V) region of the alpha chain of the T cell receptor (TCR). The TCR is a heterodimeric complex (usually consisting of alpha and beta chains) found on the surface of T lymphocytes, crucial for the adaptive immune response. The variable domains of these chains provide the antigen specificity by recognizing peptide fragments presented on major histocompatibility complex (MHC) molecules by antigen-presenting cells. The V region (such as TRAV13-2) is generated by somatic recombination, enabling the immune system's vast repertoire for antigen detection. While therapeutics do not typically target single V gene segments like TRAV13-2, they are of significant importance in TCR repertoire analysis, T cell engineering, and immune monitoring. The entire TCR, and its associated CD3 complex, are targets for immunomodulation in diseases like cancer and autoimmune conditions.

Other names
TRAV13-2TCRAV13S2TCRAV8S2TRAV132
02

Mechanism of action

Not drugged directly; mechanisms for TCR-targeted therapies include inhibition of TCR/CD3 signaling or redirection of TCR specificity (as in engineered TCR T cell therapies, bispecific T cell engagers)

03

Biological functions

Antigen recognitionImmune responseSignal transduction (as part of the TCR complex)
04

Disease associations

Cancer (role in cancer immunology, T cell specificity, and engineered TCR therapies)Infection (T cell-mediated antiviral and antibacterial responses)Autoimmune diseases (TCR specificity implicated in autoimmunity)Other (general adaptive immunity-related conditions)
05

Safety considerations

On-target, off-tumor responses (in TCR therapies)Cytokine release syndrome (for therapies engaging TCR signaling)Autoimmunity (due to loss of tolerance by aberrant TCR activation)General immunosuppression when global TCR signaling is targeted
06

Interacting drugs

None specifically for TRAV13-2; drugs and biologics target the TCR/CD3 complex (e.g., anti-CD3 antibodies, engineered TCR therapies)

1 more in the full profile.

07

Biomarkers

Rarely used as a direct biomarker; specific TCR variable regions (like TRAV13-2) can serve as markers for T cell clonality or repertoire in research or diagnostic applications, especially for immune profiling, minimal residual disease, or tracking antigen-specific T cells

Beyond the preview

Go deeper on T cell receptor alpha variable 13-2 (TRAV13-2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on T cell receptor alpha variable 13-2 (TRAV13-2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call